Research programme: transient receptor potential vanilloid 1 cation channel antagonists - AbbVie Laboratories

Drug Profile

Research programme: transient receptor potential vanilloid 1 cation channel antagonists - AbbVie Laboratories

Alternative Names: A 889425; A-425619; A-780150; A-784168; ABT-443

Latest Information Update: 01 Feb 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Abbott Laboratories
  • Developer AbbVie
  • Class Indazoles; Pyridines; Small molecules; Urea compounds
  • Mechanism of Action TRPV cation channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Preclinical Pain

Most Recent Events

  • 02 Jan 2013 Abbott separates its pharmaceuticals business to new company called AbbVie
  • 21 Oct 2011 Preclinical development is ongoing
  • 19 Nov 2008 Pharmacodynamics data from a preclinical trial presented at the 38th Annual Meeting for the Society of Neuroscience (SFN-2008)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top